Guidance for defining outcomes in clinical trials
PLOS Medicine · 21.10.2026 · 23 (10) · e1005275
DOI: 10.1371/journal.pmed.1005275 ↗Kurz gefasst
Leitlinie in der Zeitschrift PLOS Medicine, online erschienen am 21.10.2026. Verfasst von Xiangji Ying und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, University of North Carolina Gillings School of Global Public Health, Chapel Hill, North Carolina, United States of Ameri…. Hauptthemen laut MEDLINE: Clinical Trials as Topic, Endpoint Determination, Outcome Assessment, Health Care, Randomized Controlled Trials as Topic. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NLM NIH HHS, U.S. National Library of Medicine, University of North Carolina at Chapel Hill.
Abstract (Originalsprache)
Background
Defining outcomes completely before conducting clinical trials helps to mitigate concerns about reporting biases; however, there is limited guidance to help investigators define outcomes completely.
Methods
Building on a previous framework, we developed guidance for defining trial outcomes completely and consistently. We reviewed literature, developed preliminary guidance, and refined guidance iteratively through pilot testing. We randomly selected 225 randomized controlled trials (RCTs) from ClinicalTrials.gov, which evaluated 3,424 outcomes. Two raters followed a structured approach to define each outcome. When raters encountered outcomes they could not define, we refined our guidance. We continued this process until no further changes were needed. We finalized the guidance through multiple drafts and discussions among authors.
Findings
In clinical trials, a completely defined outcome includes six elements: outcome domain, specific measurement, specific metric, cutoff (if applicable), variable type, and time point. We developed guidance for naming specific measurements for both subjective and objective outcomes. We expanded on prior work by describing more comprehensive categories for specific metrics. To be consistent with the estimand framework, we replaced “method of aggregation” with two distinct elements that describe values in individuals (rather than summary measures): “variable type” and “cutoff.” We further defined “cutoff” with three sub-elements, and we defined “variable type” as whether the value for each individual is continuous or categorical.
Conclusions
Trialists and sponsors could use this framework and guidance to define outcomes in trial registrations, protocols, and results reports. When all six elements are defined, readers can better determine whether reported outcomes were prespecified and whether different trials assessed the same outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Epidemiology, University of North Carolina Gillings School of Global Public Health, Chapel Hill, North Carolina, United States of America.
- Department of Ophthalmology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States of America.
- Methods in Evidence Synthesis Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
- Department of Epidemiology and Biostatistics, Indiana University School of Public Health-Bloomington, Bloomington, Indiana, United States of America.
- Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America.
- Arkansas Children's Research Institute, Little Rock, Arkansas, United States of America.
ORCID-Profile: Xiangji Ying, Joanne E McKenzie, Matthew J Page, Kiran Ninan, Jean-Pierre Oberste, Colby J Vorland, Andrew W Brown, Riaz Qureshi, Nicholas J DeVito, Ian J Saldanha, Martin Offringa, Nancy J Butcher, Sirui Zhang, Phi-Yen Nguyen, Joe Menke, Veronica Ka Wai Lai, Halil Kilicoglu, Evan Mayo-Wilson
Förderung
- NLM NIH HHS
- U.S. National Library of Medicine
- University of North Carolina at Chapel Hill
Zitieren
APA
Ying, X., Li, T., McKenzie, J. E., Page, M. J., Ninan, K., Oberste, J. P., Vorland, C. J., Brown, A. W., Qureshi, R., DeVito, N. J., Saldanha, I. J., Offringa, M., Butcher, N. J., Zhang, S., Nguyen, P. Y., Menke, J., Lai, V. K. W., Kilicoglu, H., & Mayo-Wilson, E. (2026). Guidance for defining outcomes in clinical trials. PLOS Medicine, 23(10), e1005275. https://doi.org/10.1371/journal.pmed.1005275
Vancouver
Ying X, Li T, McKenzie JE, Page MJ, Ninan K, Oberste JP, et al. Guidance for defining outcomes in clinical trials. PLOS Medicine. 2026;23(10):e1005275. doi:10.1371/journal.pmed.1005275
BibTeX
@article{Ying2026,
author = {Ying, Xiangji and Li, Tianjing and McKenzie, Joanne E and Page, Matthew J and Ninan, Kiran and Oberste, Jean-Pierre and Vorland, Colby J and Brown, Andrew W and Qureshi, Riaz and DeVito, Nicholas J and Saldanha, Ian J and Offringa, Martin and Butcher, Nancy J and Zhang, Sirui and Nguyen, Phi-Yen and Menke, Joe and Lai, Veronica Ka Wai and Kilicoglu, Halil and Mayo-Wilson, Evan},
title = {Guidance for defining outcomes in clinical trials},
journal = {PLOS Medicine},
year = {2026},
volume = {23},
number = {10},
pages = {e1005275},
doi = {10.1371/journal.pmed.1005275}
}
EUVIMED